PIERIS PHARMACEUTICALS INC (PIRS) Stock Price & Overview
NASDAQ:PIRS • US7207952026
Current stock price
The current stock price of PIRS is 13.6 USD. Today PIRS is down by -15.69%. In the past month the price decreased by -14.73%. In the past year, price increased by 2.97%.
PIRS Key Statistics
- Market Cap
- 108.392M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -12.61
- Dividend Yield
- N/A
PIRS Stock Performance
PIRS Stock Chart
PIRS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PIRS. When comparing the yearly performance of all stocks, PIRS is a bad performer in the overall market: 72.72% of all stocks are doing better.
PIRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PIRS. The financial health of PIRS is average, but there are quite some concerns on its profitability.
PIRS Earnings
PIRS Forecast & Estimates
For the next year, analysts expect an EPS growth of 42.86% and a revenue growth -79.28% for PIRS
PIRS Groups
Sector & Classification
PIRS Financial Highlights
Over the last trailing twelve months PIRS reported a non-GAAP Earnings per Share(EPS) of -12.61. The EPS increased by 54.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.74% | ||
| ROE | -98.06% | ||
| Debt/Equity | 0 |
PIRS Ownership
PIRS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.6 | 365.463B | ||
| AMGN | AMGEN INC | 14.81 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.03 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.1 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.14 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.71 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.23 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PIRS
Company Profile
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Company Info
IPO: 2014-12-18
PIERIS PHARMACEUTICALS INC
225 Franklin Street, 26th Floor
Boston MASSACHUSETTS 02109 US
CEO: Stephen S. Yoder
Employees: 48
Phone: 18572468998
PIERIS PHARMACEUTICALS INC / PIRS FAQ
Can you describe the business of PIERIS PHARMACEUTICALS INC?
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
What is the stock price of PIERIS PHARMACEUTICALS INC today?
The current stock price of PIRS is 13.6 USD. The price decreased by -15.69% in the last trading session.
Does PIERIS PHARMACEUTICALS INC pay dividends?
PIRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of PIRS stock?
PIRS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of PIERIS PHARMACEUTICALS INC (PIRS) based on its PE ratio?
PIERIS PHARMACEUTICALS INC (PIRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.61).
What is the expected growth for PIRS stock?
The Revenue of PIERIS PHARMACEUTICALS INC (PIRS) is expected to decline by -79.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns PIERIS PHARMACEUTICALS INC?
You can find the ownership structure of PIERIS PHARMACEUTICALS INC (PIRS) on the Ownership tab.